Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce?
Open Access
- 2 December 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 68 (4), 731-742
- https://doi.org/10.1093/jac/dks469
Abstract
Twenty-five years ago, isolation of vancomycin-resistant Enterococcus faecium (VREm) was reported both in the UK and in France. Since then, VREm has spread worldwide in hospitals. Hospital outbreaks appeared to be related to the evolution since the end of 1980s of a subpopulation of E. faecium highly resistant to ampicillin and fluoroquinolones (the so-called clonal complex CC17) that later acquired resistance to vancomycin. CC17 isolates are presumably better adapted than other E. faecium isolates to the constraints of the hospital environment and most contain mobile genetic elements, phage genes, genes encoding membrane proteins, regulatory genes, a putative pathogenicity island and megaplasmids. Colonization and persistence are major features of VREm. Inherent characteristics of E. faecium including a remarkable genome plasticity, in part due to acquisition of IS elements, in particular IS16, have facilitated niche adaptation of this distinct E. faecium subpopulation that is multiply resistant to antibiotics. Quinupristin/dalfopristin and linezolid are licensed for the treatment of VREm infections, with linezolid often used as a first-line treatment. However, the emergence of plasmid-mediated resistance to linezolid by production of a Cfr methyltransferase in Enterococcus faecalis is worrying. Daptomycin has not been extensively evaluated for the treatment of VREm infections and resistant mutants have been selected under daptomycin therapy. Although control of VRE is challenging, a laissez-faire policy would result in an increased number of infections and would create an irreversible situation. Although so far unsuccessful, dissemination of glycopeptide-resistant Staphylococcus aureus with van genes acquired from resistant enterococci cannot be ruled out.Keywords
This publication has 99 references indexed in Scilit:
- Vancomycin-Resistant Staphylococcus aureus in the United States, 2002-2006Clinical Infectious Diseases, 2008
- Vancomycin Resistance in Gram-Positive CocciClinical Infectious Diseases, 2006
- Debate—Guidelines for control of glycopeptide-resistant enterococci (GRE) have not yet workedJournal of Hospital Infection, 2004
- Vancomycin-resistant enterococci: why are they here, and where do they come from?The Lancet Infectious Diseases, 2001
- Avoparcin and virginiamycin as animal growth promoters: a plea for science in decision-makingClinical Microbiology & Infection, 2000
- Emergence of vancomycin-resistant enterococci in New York CityThe Lancet, 1993
- Co-transfer of vancomycin and other resistance genes fromEnterococcus faecalisNCTC 12201 toStaphylococcus aureusFEMS Microbiology Letters, 1992
- Structure, biochemistry and mechanism of action of glycopeptide antibioticsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1989
- Plasmid-Mediated Resistance to Vancomycin and Teicoplanin in Enterococcus FaeciumNew England Journal of Medicine, 1988
- THE DRAMA.The Lancet, 1823